Beijing Wantai Biological Pharmacy Enterprise Co.

Beijing, China

Beijing Wantai Biological Pharmacy Enterprise Co.

Beijing, China
SEARCH FILTERS
Time filter
Source Type

Receive press releases from iHealthcareAnalyst, Inc.: By Email Hepatitis E Diagnostic Tests Market by Test Types, End Users, Growth Trends and Forecast to 2021, Upcoming Report by iHealthcareAnalyst, Inc. Hepatitis E Diagnostic Tests Market by Test Type (ELISA HEV IgM Test Kits, ELISA HEV IgG Test Kits, RT-PCR Test Kits, Others), End Users (Diagnostic Laboratories, Hospitals, Point-of-Care) and Forecast 2017-2021. Maryland Heights, MO, April 30, 2017 --( Browse Hepatitis E Diagnostic Tests Market by Test Type (ELISA HEV IgM Test Kits, ELISA HEV IgG Test Kits, RT-PCR Test Kits, Others), End Users (Diagnostic Laboratories, Hospitals, Point-of-Care) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/hepatitis-e-diagnostics-market/ The global hepatitis E diagnostic tests market segmentation is based on test type (ELISA HEV IgM test kits, ELISA HEV IgG test kits, RT-PCR test kits, Others), end users (diagnostic laboratories, hospitals, point-of-care). The global hepatitis E diagnostic tests market report provides market size (Revenue USD Million 2014 to 2021), market share, trends and forecasts growth trends (CAGR%, 2017 to 2021). The global hepatitis E diagnostic tests market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global hepatitis E diagnostic tests market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market. Major players operating in the global hepatitis E diagnostic tests market and profiled in this report include Altana Diagnostics GmbH, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Biokit S.A., Dia.Pro - Diagnostic Bioprobes s.r.l, F. Hoffmann-La Roche Ltd., Fast-track diagnostics Ltd., Fortress Diagnostics Limited, Mikrogen GmBH, MP Biomedicals, LLC, and Primerdesign Ltd. 1. Test Type 1.1. ELISA HEV IgM Test Kits 1.2. ELISA HEV IgG Test Kits 1.3. RT-PCR Test Kits 1.4. Others 2. End Users 2.1. Diagnostic Laboratories 2.2. Hospitals 2.3. Point-of-Care 2.4. Research Centers 3. Geography (Region, Country) 3.1. North America (U.S., Canada) 3.2. Latin America (Brazil, Mexico, Rest of LA) 3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU) 3.4. Asia Pacific (Japan, China, India, Rest of APAC) 3.5. Rest of the World 4. Company Profiles 4.1. Altana Diagnostics GmbH 4.2. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. 4.3. Biokit S.A. 4.4. Dia.Pro - Diagnostic Bioprobes s.r.l 4.5. F. Hoffmann-La Roche Ltd. 4.6. Fast-track diagnostics Ltd. 4.7. Fortress Diagnostics Limited 4.8. Mikrogen GmBH 4.9. MP Biomedicals, LLC 4.10. Primerdesign Ltd. To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/hepatitis-e-diagnostics-market/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, April 30, 2017 --( PR.com )-- Hepatitis E is a liver disease caused by the hepatitis E virus (HEV), and the infection is found worldwide but most common in developing countries with limited access to essential water, sanitation, hygiene and health services. The commonly used tests for HEV infection include detection of IgM and IgG anti-HEV antibodies and detection of HEV RNA. Diagnosis of hepatitis E infection is usually based on the detection of specific IgM antibodies (ELISA). Additional tests include reverse transcriptase polymerase chain reaction (RT-PCR) to detect the hepatitis E virus RNA in blood and/or stool samples, carried out in specialized laboratory facilities. Recently, a test for viral antigen detection in serum has been developed. Although several diagnostic assays for anti-HEV antibodies are available, they have undergone fairly limited testing and often provide discordant results, particularly for IgG antibodies. Improved validation of existing anti-HEV antibody assays or development of new assays with superior performance characteristics is urgently needed.Browse Hepatitis E Diagnostic Tests Market by Test Type (ELISA HEV IgM Test Kits, ELISA HEV IgG Test Kits, RT-PCR Test Kits, Others), End Users (Diagnostic Laboratories, Hospitals, Point-of-Care) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/hepatitis-e-diagnostics-market/The global hepatitis E diagnostic tests market segmentation is based on test type (ELISA HEV IgM test kits, ELISA HEV IgG test kits, RT-PCR test kits, Others), end users (diagnostic laboratories, hospitals, point-of-care).The global hepatitis E diagnostic tests market report provides market size (Revenue USD Million 2014 to 2021), market share, trends and forecasts growth trends (CAGR%, 2017 to 2021). The global hepatitis E diagnostic tests market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global hepatitis E diagnostic tests market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.Major players operating in the global hepatitis E diagnostic tests market and profiled in this report include Altana Diagnostics GmbH, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Biokit S.A., Dia.Pro - Diagnostic Bioprobes s.r.l, F. Hoffmann-La Roche Ltd., Fast-track diagnostics Ltd., Fortress Diagnostics Limited, Mikrogen GmBH, MP Biomedicals, LLC, and Primerdesign Ltd.1. Test Type1.1. ELISA HEV IgM Test Kits1.2. ELISA HEV IgG Test Kits1.3. RT-PCR Test Kits1.4. Others2. End Users2.1. Diagnostic Laboratories2.2. Hospitals2.3. Point-of-Care2.4. Research Centers3. Geography (Region, Country)3.1. North America (U.S., Canada)3.2. Latin America (Brazil, Mexico, Rest of LA)3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)3.4. Asia Pacific (Japan, China, India, Rest of APAC)3.5. Rest of the World4. Company Profiles4.1. Altana Diagnostics GmbH4.2. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.4.3. Biokit S.A.4.4. Dia.Pro - Diagnostic Bioprobes s.r.l4.5. F. Hoffmann-La Roche Ltd.4.6. Fast-track diagnostics Ltd.4.7. Fortress Diagnostics Limited4.8. Mikrogen GmBH4.9. MP Biomedicals, LLC4.10. Primerdesign Ltd.To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/hepatitis-e-diagnostics-market/About UsiHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill DriveMaryland Heights, MO 63043United StatesEmail: sales@ihealthcareanalyst.comWebsite: https://www.ihealthcareanalyst.com Click here to view the list of recent Press Releases from iHealthcareAnalyst, Inc.


Patent
Xiamen University and Beijing Wantai Biological Pharmacy Enterprise Co. | Date: 2016-11-14

The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.


Patent
Xiamen University and Beijing Wantai Biological Pharmacy Enterprise Co. | Date: 2015-08-26

The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.


Patent
New Jersey Medical School, Beijing Wantai Biological Pharmacy Enterprise Co. and Xiamen University | Date: 2012-06-06

Provided are an ORF7 deficient varicella virus, an vaccine comprising the virus and use thereof, as well as a method for the production the virus.


Patent
Xiamen University and Beijing Wantai Biological Pharmacy Enterprise Co. | Date: 2015-08-19

The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.


Patent
New Jersey Medical School, Xiamen University and Beijing Wantai Biological Pharmacy Enterprise Co. | Date: 2010-07-27

Provided are an ORF7 deficient varicella virus, an vaccine comprising the virus and use thereof, as well as a method for the production the virus.


Patent
Beijing Wantai Biological Pharmacy Enterprise Co. and Xiamen University | Date: 2011-03-23

The present invention relates to polypeptide(s) comprising the amino acid sequence as set forth in SEQ ID No. 1 of hepatitis E virus ORF 2 or its fragment, which is in the form of n-polymeric polypeptide, wherein n is an integer from 1-180; to a chimeric protein consisting of a polypeptide of the present invention and a conserved fragment of hemagglutin antigen from influenza virus; to a polypeptide of the present invention bound to a polypeptide containing epitope from hepatitis E virus ORF3 or an immunogenic fragment thereof; to a recombinant expression vector comprising the DNA molecule encoding the above polypeptides and the host cell transformed with said recombinant expression vector which is able to express polypeptide of the present invention. The present invention further relates to a vaccine composition against hepatitis E virus which comprises the above-mentioned polypeptide, or diagnostic kit for hepatitis E virus infection comprising the above-mentioned polypeptide, which includes IgG, IgM, or total antibody diagnostic kit for hepatitis E virus, and to the use of vaccine composition and diagnostic kit for prophylaxis, diagnosis and/or treatment of hepatitis E virus infection.


Patent
Xiamen University and Beijing Wantai Biological Pharmacy Enterprise Co. | Date: 2014-04-09

The present invention provides monoclonal antibodies that bind specifically to H5 subtype avian influenza virus hemagglutinin (HA) proteins, and can block the binding activity of at least 50% of the known monoclonal antibodies to the H5 subtype avian influenza virus hemagglutinin (HA) protein. The monoclonal antibodies can be used for the detection, diagnosis, prevention, and treatment of avian influenza viruses, especially the H5 subtype of avian influenza viruses. The present invention also provides the related hybridoma cell lines, isolated nucleic acid molecules and short peptides, as well as medical composition and medical diagnostic equipment and kit containing the monoclonal antibody.


Patent
Beijing Wantai Biological Pharmacy Enterprise Co. and Xiamen University | Date: 2014-04-08

The invention relates to a truncated L1 protein of the Human Papillomavirus Type 6, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.


Patent
Beijing Wantai Biological Pharmacy Enterprise Co. | Date: 2011-05-18

The present invention relates to monoclonal antibody specifically binding to polypeptide(s) comprising the amino acid sequence as set forth in SEQ ID No. 1 of hepatitis E virus ORF 2 or its conserved variants or its active fragments, or other monoclonal antibodies against ORF2 which can cross react with said monoclonal antibody of present invention, and its nucleotide sequence or its degenerate sequence; to the antigenic determinant in hepatitis E virus ORF2; to a method for screening isolated or recombined polypeptide or polypeptide analog, which has the same property of specifically binding said monoclonal antibody 8C11 and/or 8H3 as said antigenic determinant 1) or 3) of hepatitis E virus ORF2; to polypeptide or polypeptide analog screened by the method above and its nucleotide sequence or degenerate sequence; to a use of said polypeptide or polypeptide analog in preparation of a medicament for the diagnosis and/or precaution of hepatitis E virus infection; to a diagnostic kit for hepatitis E virus infection and a vaccine composition for prophylaxis of hepatitis E virus infection; to use of said monoclonal antibodies or their active fragments or conserved variants in preparation of a medicament for diagnosis, prophylaxis and/or treatment of hepatitis E virus infection; to pharmaceutical composition for prophylaxis and/or treatment of hepatitis E virus infection and a method for prophylaxis and/or treatment of hepatitis E virus infection; to a recombinant expression vector comprising said nucleotide molecule in present invention and a host cell transformed with said recombinant expression vector that is able to express monoclonal antibody and its conserved variants or active fragments or polypeptide or polypeptide analogs.

Loading Beijing Wantai Biological Pharmacy Enterprise Co. collaborators
Loading Beijing Wantai Biological Pharmacy Enterprise Co. collaborators